Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Phase 2 Active not recruiting 12 enrolled Memorial Sloan Kettering Cancer Center Sanofi · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.

Timeline

Start: 2023-07-21
Primary completion: 2027-06-29
Completion: 2027-06-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Isatuximab	Monoclonal antibody	—	Intravenous

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Summary

Timeline

Drugs

Indications